Login
From:
CNBC
(Uncensored)
subscribe
Biogen CEO says $56,000 annually for Alzheimer’s drug is 'fair,' promises not to hike price for at least 4 years
https://www.cnbc.com/2021/06/07/biogen-ceo-says-56000-annually-for-alzheimers-drug-is-fair-promises-not-to-hike-price-for-at-least-4-years.html
links
backlinks
Tagged with:
biotechnology
business
politics
u.s. economy
health care industry
breaking news business
biotech and pharmaceuticals
biogen inc
Biogen CEO Michel Vounatsos told CNBC that the list price of $56,000 per year for the company's FDA-approved Alzheimer's disease drug aducanumab is "fair."
Roast topics
Find topics
Roast it!
Roast topics
Find topics
Find it!
Roast topics
Find topics
Find it!
